Fractionation and protraction for radiotherapy of prostate carcinoma

• Published in: International journal of radiation oncology, biology, physics Vol. 43; no. 5; pp. 1095 - 1101
• Main Authors: Brenner, David J, Hall, Eric J
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.03.1999; Elsevier
• Subjects: Biological and medical sciences; Brachytherapy - standards; Dose Fractionation, Radiation; HDR; Humans; Hypofractionation; Male; Medical sciences; Models, Biological; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radiation therapy and radiosensitizing agent; Radiobiology; Radiotherapy; Treatment with physical agents; Treatment. General aspects; Tumors; Hypofractionation; Radiotherapy; Prostate cancer; HDR; Adenocarcinoma; Human; Urinary system disease; Prostate disease; Male; Malignant tumor; Dose rate; Fractionated dose; Treatment; Male genital diseases; High dose; Prostate
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/S0360-3016(98)00438-6

Purpose: To investigate whether current fractionation and brachytherapy protraction schemes for the treatment of prostatic cancer with radiation are optimal, or could be improved. Methods and Materials: We analyzed two mature data sets on radiotherapeutic tumor control for prostate cancer, one using EBRT and the other permanent seed implants, to extract the sensitivity to changes in fractionation of prostatic tumors. The standard linear-quadratic model was used for the analysis. Results: Prostatic cancers appear significantly more sensitive to changes in fractionation than most other cancers. The estimated α/β value is 1.5 Gy [0.8, 2.2]. This result is not too surprising as there is a documented relationship between cellular proliferative status and sensitivity to changes in fractionation, and prostatic tumors contain exceptionally low proportions of proliferating cells. Conclusions: High dose rate (HDR) brachytherapy would be a highly appropriate modality for treating prostate cancer. Appropriately designed HDR brachytherapy regimens would be expected to be as efficacious as low dose rate, but with added advantages of logistic convenience and more reliable dose distributions. Similarly, external beam treatments for prostate cancer can be designed using larger doses per fraction; appropriately designed hypofractionation schemes would be expected to maintain current levels of tumor control and late sequelae, but with reduced acute morbidity, together with the logistic and financial advantages of fewer numbers of fractions.